哌仑西平短程治疗消化性溃疡23例

本文应用哌合西平(50mg,bid)治疗消化性溃疡23例与西咪替丁(1.0g/d)组26例进行对照研究。疗程均为6wk,由内窥镜检查评定疗效。结果表明,哌仑西平与西咪替丁2组溃疡愈合有效率分别为61％(14/23)与81％(21/26);2组止痛有效率分别为65％(15/23)与33％(6/18),均无统计学差异。因此,哌仑西平对消化性溃疡的疗效与西咪替丁相似。哌仑西平组的不良反应有口干、视力模糊等,似较西咪替丁组为多。     

西咪替丁预防肺心病呼吸衰竭并发上消化道出血

用西咪替丁400mg溶于10％葡萄糖液300mL中静滴,qd。治疗肺心病呼吸衰竭病人14例(男12,女2;平均年龄65±s 10a),20d为一个疗程。常规组14例,除未用西咪替丁外,其他治疗和疗程同治疗组。结果治疗组无1例并发上消化道出血,常规组则有4例。提示西咪替丁预防肺心病呼吸衰竭并发上消化道出血有效。     

西咪替丁治疗婴幼儿腹泻

本文采用西咪替丁20-30mg/(kg·d),分3次用生理盐水稀释后静脉注射(q6h)治疗婴幼儿秋季腹泻51例,与51例单纯补液组、50例庆大霉素组比较,西咪替丁缩短腹泻天数与2组对照组差异均有非常显著的意义,P<0.01。退热天数亦较对照组短,P<0.05。未见明显不良反应。     

法莫替丁与雷尼替丁治疗十二指肠溃疡的比较

70例活动性十二指肠溃疡(DU)患者分2组,38例每晚服用40mg法莫替丁(Fam),男29例,女9例,平均年龄44±12a。32例每晚服300mg雷尼替丁(Ran),男25例,女7例,平均年龄39±8a。经4wk治疗后胃镜复查,2组溃疡愈合例数分别为23例(60％)和20例(62％),无显著差异。但Ran组中6例(19％)无效,而Fam组中38例(100％)有效。2组有效例数比较有非常显著差异P<0.01。     

马来酸曲美布汀在胃切除术后溃疡治疗中的应用

目的探讨马来酸曲美布汀在胃切除术后溃疡中的疗效。方法将34例患者分为2组,对照组患者14例接受奥美拉唑和铝碳酸镁咀嚼片治疗,实验组20例在此基础上接受马来酸曲美布汀,4周后复查胃镜。结果实验组溃疡愈合率显著高于对照组,差异有统计学意义(P<0.05)。结论马来酸曲美布汀有利于胃切除术后溃疡的愈合。     

复方四逆散治疗消化性溃疡的临床观察

目的观察"复方四逆散"治疗消化性溃疡的临床疗效。方法运用随机分组法将门诊消化性溃疡患者分成两组,治疗组116例,煎服复方四逆散每日两次,早晚各服150mL,同时与对照组32例口服西咪替丁(0.2g/片)每日2次,1次1片,4周为1个疗程,治疗期间禁酸辣、生冷饮食及难消化食物,忌烟酒。1～2个疗程后作胃镜及临床症状对比观察。结果 1～2个疗程结束,两组间症状疗效与胃镜检查无显著差异,但1年后复查情况表明,复方四逆散加减复发率明显低于西咪替丁组。结论复方四逆散治疗消化性溃疡远期疗效理想,值得临床推广使用。     

静脉注射奥美拉唑治疗十二指肠球部溃疡并出血20例

目的:观察静脉注射奥美拉唑治疗十二指肠球部溃疡（球溃疡）并出血的临床疗效。方法:42例上消化道出血患者均于入院后24h内行胃镜确诊为球溃疡,并随机分为2组,奥美拉唑组（治疗组）20例应用奥美拉唑静脉注射治疗,对照组22例应用西咪替丁、酚磺乙胺注射液（止血定）联合静脉滴注。结果:治疗组显效率85％,总有效率95％,平均止血时间缩短,输血量减少,与对照组比较有显著性差异（P<0.01）。结论:静脉注射奥美拉唑治疗球溃疡并出血疗效可靠,止血迅速,副作用少,值得临床推广使用。     

西咪替丁与阿昔洛韦联用治疗水痘20例观察

目的：观察西咪替丁与阿昔洛韦联用治疗水痘的临床疗效。方法：将35例患儿随机分为治疗组和对照组,治疗组（20例）采用西咪替丁与阿昔洛韦联用,对照组（15例）服用病毒灵与板兰根冲剂。结果：治疗组有效率85％,疗效明显优于对照组60％,（P＜0．05）。结论：西咪替丁与阿昔洛韦联用治疗水痘疗效肯定。     

外用重组人表皮生长因子凝胶联合西咪替丁对复发性阿弗他溃疡患者溃疡愈合情况的影响

目的:探讨外用重组人表皮生长因子凝胶联合西咪替丁对复发性阿弗他溃疡患者溃疡愈合情况的影响.方法:对我院收治的141例复发性阿弗他溃疡患者进行研究.将患者按照随机数字表法平均分为三组,对照组、观察组和空白组各47例.对照组患者服用西咪替丁治疗,观察组予外用重组人表皮生长因子凝胶联合西咪替丁进行治疗,空白组完全不用药.比较分析三组的临床疗效,炎症因子水平、疼痛消失时间和溃疡愈合时间、不良反应发生情况.结果:观察组治疗后的总有效率是95.74％,明显高于对照组的78.72％和空白组的76.60％,差异具有统计学意义(P<0.05);治疗后,白细胞介素-1(IL-1)、肿瘤坏死因子(TNF-α)、白细胞介素-6(IL-6)等炎症因子水平均下降,且观察组显著低于对照组及空白组,对照组显著低于空白组,差异均存在统计学意义(P<0.05).观察组患者疼痛消失、溃疡痊愈时间显著短于对照组及空白组,对照组短于空白组,差异均存在统计学意义(P<0.05).对照组的不良反应发生率为14.89％,观察组为10.64％,差异无统计学意义(P>0.05).结论:外用重组人表皮生长因子凝胶联合西咪替丁治疗复发性阿弗他溃疡患者临床疗效显著,可有效降低炎症因子水平,促进患者溃疡愈合,且安全性较高.     

三联疗法治疗胃及十二指肠溃疡疗效观察

目的观察奥美拉唑,阿莫西林及甲硝唑三联疗法治疗十二指肠溃疡的临床疗效。方法将132例十二指肠溃疡患者随机分为2组。治疗组66例采用西药三联疗法(奥美拉唑,阿莫西林及甲硝唑)治疗;对照组66例,单服法莫替丁20mg,2次/d。两组疗程均为4周。结果治疗组临床总有效率92.5%,胃镜1年内复发率8.1%;对照组临床总有效率81.82%,胃镜1年复发率42.59%。与对照组比较差异有统计学意义(P<0.05)。结论奥美拉唑,阿莫西林及甲硝唑三联疗法治疗胃及十二指肠溃疡,可显著提高治愈率及降低复发率,具有较好的临床疗效。     

法莫替丁治疗消化性溃疡

经胃镜证实活动性消化性溃疡用双盲对照法,23例(男21例,女2例,年龄41±11a)服法莫替丁20mg bid;另17例(男14例,女3例,年龄40±14a)服雷尼替丁150mg bid。十二指肠和胃溃疡分别于服药后4wk和6wk复查胃镜,结果法莫替丁显效率96％,雷尼替丁为94％,2组无显著差异。     

Famotidine in the short-term treatment of duodenal ulcer and of concomitant peptic lesions: comparison with cimetidine

Twenty patients affected with endoscopically demonstrated duodenal ulcer were studied. They were randomly divided into two groups of ten individuals each. The first group was treated with famotidine 40 mg/die/os, the second one with cimetidine 800 mg/die/os; both drugs were administered in one medication at bedtime. In each group, eight patients completed the treatment: six out of eight famotidine treated and five out of eight cimetidine treated patients showed ulcer healing on upper digestive endoscopy after four weeks of treatment; after eight weeks of therapy, all patients of both groups displayed ulcer healing. Nevertheless, an overall quantitative evaluation of all peptic lesions (performed according to an endoscopic arbitrary score) indicated a higher effectiveness of famotidine. Famotidine did not affect humoral parameters of renal, hepatic and myelopoietic function and did not significantly change fasting serum gastrin levels.     

醋氨己酸锌治疗肝硬化合并消化性溃疡

目的 :观察醋氨己酸锌对肝硬化合并消化性溃疡的疗效。方法 :肝硬化合并十二指肠溃疡 36例和合并胃溃疡 30例 ,随机分为醋氨己酸锌组 (醋氨己锌 0 .3g ,po ,tid ,其中胃溃疡 12例、十二指肠溃疡 12例 )、法莫替丁组 (法莫替丁 2 0mg ,po ,bid ,其中胃溃汤 9例、十二指肠溃疡 10例 )、联合用药组 (醋氨己酸锌 0 .3g ,po ,tid ,法莫替丁 2 0mg ,po ,bid ,其中胃溃疡 9例、十二指肠溃疡 14例 ) ,共3组。治疗胃溃疡疗程 6wk ,十二指肠溃疡疗程为4wk ,疗程结束后 ,用内窥镜观察溃疡愈合情况。结果 :醋氨己酸锌组肝硬化合并胃溃疡和十二肠溃疡的愈合率分别为 5 8% ,6 6 % ,法莫替丁组分别为5 6 % ,70 % ,联合用药组分别为 78% ,79% ,3组比较差异无显著意义 ,P >0 .0 5。结论 :醋氨己酸锌治疗肝硬化合并消化性溃疡的疗效与其他 2组相似 ,但其安全性好     

奥美拉唑对65例消化性溃疡的疗效

奥美拉唑20mg,qd,口服治疗活动性胃或十二指肠溃疡65例(Ome组:男59,女6;年龄41±13a)。雷尼替丁0.15g,bid,口服,治疗42例(Ran组:男39,女3;年龄42±11a)作比较。疗程4-6wk。服药后疼痛消除:Ome组90％在3d内,Ran组92％需7-8d。十二指肠溃疡愈合率:Ome组(43例)4wk达100％,Ran组(30例)70％(P<0.01),胃溃疡愈合率:Ome组(22例)6wk为95％,Ran组(12例)67％(P<0.01)     

洛赛克、法莫替丁治疗十二指肠球部溃疡出血的疗效对比

目的：观察洛寒克与法莫替丁对十二指肠球部溃疡出血的疗效。方法：116例十二指肠球部溃疡出血病人随机分为两组，治疗组给予洛赛克40mg静脉滴注或推注，每天1次。对照组给予法莫替丁20mg静脉滴注，在2次。两组疗程均为3－5天。结果：治疗组总有效率为96．2％，对照组总有效率为84．4％，组间比较有显著性差异（P＜0．01）。结论：洛赛克与法莫替丁治疗十二指中溃疡出血均有较好疗效，但洛赛克疗效更好，止血更快。     

法莫替丁粉针剂与注射液治疗消化性溃疡合并出血的比较

目的：比较法莫替丁粉针剂与注射液治疗消化性溃疡合并出血的疗效和安全性。方法：法莫替丁粉针组１００例（Ａ组）给该粉针剂２０ｍｇ加入０．９％氯化钠注射液２０ｍＬ，ｂｉｄ，ｉｖ；法莫替丁注射液组５０例（Ｂ组）给法莫替丁葡萄糖注射液２５０ｍＬ（含法莫替丁２０ｍｇ），ｂｉｄ，ｉｖ，ｇｔ，疗程均为４ｗｋ。结果：Ａ和Ｂ组止血效果分别为８９％和８４％，（Ｐ＞０．０５）；５ｄ内上腹部疼痛缓解率分别为８５％和８２％，（Ｐ＞０．０５）。２组疗效综合评价分别为８７％和８４％（Ｐ＞０．０５）；不良反应发生率分别是２２％和２８％，（Ｐ＞０．０５）。结论：粉针剂与注射液的疗效和安全性相似。     

Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration

Lansoprazole (AG 1749/CG 4801) is an inhibitor of gastric acid secretion by blocking H+,K(+)-ATPase. In this 2:1 randomized, double-blind, multicentre trial lansoprazole 30 mg am was compared to 40 mg famotidine nocte in 264 out-patients suffering from uncomplicated duodenal ulcer. After 2 weeks of treatment ulcer healing was confirmed endoscopically in a significantly higher proportion (P = 0.027) of patients treated with lansoprazole (94/174 = 54.0%) compared to patients receiving famotidine (35/90 = 38.9%). Cumulative healing rates after 4 weeks were 91.4% for the lansoprazole group and 83.3% for the famotidine group (P = 0.065). Pain relief and decrease of concomitant antacid consumption during treatment were comparable in both groups. Both compounds were well tolerated. Rates of recurrent duodenal ulcer in the 6 months after trial treatment were 45/158 (28.5%) after lansoprazole, and 18/69 (26.1%) after famotidine.     

High dose famotidine in ranitidine resistant severe oesophagitis: a pilot study

Fifty-three asymptomatic patients who, in spite of continuous treatment with ranitidine 300 mg bid for six months, had active severe oesophagitis, Savary and Miller grade III-IV or Barretts ulceration at endoscopy were treated with high dose famotidine. In the severe oesophagitis group famotidine 40 mg bid, 13/29 (44%) healed at eight weeks and 17/29 (58%) at sixteen weeks. In the Barrett's ulcer group famotidine 40 mg tid, 10/24 (41%) healed at eight weeks and 18/24 (75%) at sixteen weeks. Famotidine in high doses was well tolerated in this age group (mean 66.75 years), with 5/53 (9%) minor adverse events recorded. Famotidine in high dose is effective in the treatment of ranitidine resistant severe oesophagitis or Barrett's ulceration.     

注射用泮托拉唑治疗上消化道出血临床观察

目的观察泮托拉唑治疗上消化道出血的临床疗效及安全性。方法对162例临床确诊的上消化道出血患者随即双盲分为观察组(80例)和对照组(82例),观察组给予注射用泮托拉唑80mg静脉滴注,2次/d,疗程3～5d,对照组给予法莫替丁20mg静脉滴注,2次/d,疗程3～5d,观察两组给药后72h及120h临床症状改善,实验室指标或内镜下止血征象。结果观察组与对照组,显效率分别为47.50%、26.83%,总有效率分别为96.25%、69.51%,观察组的疗效优于对照组,差异有统计学意义(P<0.05)。结论注射用泮托拉唑治疗上消化道出血效果显著,不良反应轻微,适合临床应用。